https://specialty.mims.com/topic/does-atezolizumab-improve-os-in-patients-with-resected-nsclc-and-pd-l1--1-percent-
0
0
10/16/22 at 3:00am
Organization
Mims.com
Author
Roshini Claire Anthony
The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive...
Create an account
or login to join the discussion